$6.66
+0.20 (+3.10%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DERM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 8 with posted results
Held by 8 tracked-famous managers (JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, +3 more) · FINRA short interest 20.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.NCT05296629results2024-12-03Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: DFD-29, Doxycycline, Placebo | Papulopustular Rosacea | 323 | 2023-06-30actual | 2024-12-03 |
| A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)NCT05343455results2024-12-03Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: DFD-29, Doxycycline, Placebo | Papulopustular Rosacea | 330 | 2023-06-30actual | 2024-12-03 |
| Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 WeeksNCT05597462Changes in the number of colony forming units (CFUs) of microbial species.Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: Minocycline hydrochloride capsules · Other: Placebo | Rosacea | 60 | 2023-05-30actual | 2023-08-02 |
| A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human SubjectsNCT05452785Peak Plasma Concentration (Cmax) of DFD-29 compared to Solodyn(R)Randomized · Open-label · Other | Phase 1 | Completed | Drug: DFD-29 (Minocycline) Fasting, DFD-29 (Minocycline) Fed, Solodyn (Minocycline) Fasting | Pharmacokinetics | 24 | 2022-05-25actual | 2023-03-02 |
| A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar HyperhidrosisNCT03880266results2021-03-15Mean Change From Baseline to Week 2 in Hand Sweating Severity ScoreRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Glycopyrronium cloth, 2.4%, Vehicle | Palmar Hyperhidrosis | 72 | 2019-05-24actual | 2021-08-25 |
| Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary HyperhidrosisNCT02553798results2018-09-25Long-term Safety Assessed Through Adverse Events and Local Skin ReactionsOpen-label · Treatment | Phase 3 | Completed | Drug: Glycopyrronium Topical Wipes | Hyperhidrosis | 564 | Dec 2016actual | 2021-08-25 |
| Study of Glycopyrronium in Subjects With Axillary HyperhidrosisNCT02530294results2018-08-14Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of Axillary Sweating Daily Diary (ASDD) Item #2 From Baseline at Week 4Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: glycopyrronium Topical Wipes · Other: Vehicle | Hyperhidrosis | 353 | Apr 2016actual | 2021-08-25 |
| Study of Glycopyrronium in Axillary HyperhydrosisNCT02530281results2018-08-14Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of ASDD Item #2 From Baseline at Week 4Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: glycopyrronium Topical Wipes · Other: Vehicle | Hyperhidrosis | 344 | Mar 2016actual | 2021-08-25 |
| Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary HyperhidrosisNCT02129660results2018-09-04Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD · Other: Vehicle | Hyperhidrosis | 105 | Jan 2015actual | 2025-09-17 |
| A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary HyperhidrosisNCT02016885results2018-09-13Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0% · Other: Vehicle | Hyperhidrosis | 198 | Sep 2014actual | 2021-08-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19